Sambrinvest
Sambrinvest S.A. is a private equity and venture capital firm located in Gosselies, Belgium, established in 1985. The firm specializes in direct and fund of funds investments, focusing on small and medium-sized enterprises primarily in the Charleroi Sud-Hainaut and Thuin districts. Sambrinvest targets various sectors including agri-food, audiovisual, gaming, automotive, biotechnology, pharmaceuticals, construction, digital technology, environmental solutions, alternative energy, manufacturing, and real estate, while excluding retail, hospitality, and banking. The firm typically invests through minority stakes, subordinated loans, and other financial instruments, with investment amounts generally not exceeding €1.25 million in companies with revenues below €50 million. Sambrinvest is recognized as an active venture capital player in its region and remains open to opportunities in additional sectors.
34 past transactions
ATB Therapeutics
Series A in 2024
ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.
AdipoPharma
Venture Round in 2024
AdipoPharma SAS focuses on advancing treatments for insulin resistance and type 2 diabetes by harnessing the unique properties of adipocyte cells. The company develops peptide-based drugs aimed at improving insulin sensitivity and controlling blood glucose levels in patients. AdipoPharma's approach involves a comprehensive genetic analysis of conditions such as Alström syndrome and utilizes therapeutic peptides that target specific pathways to enhance lipid biosynthesis in diseased adipocytes. This targeted methodology not only addresses insulin resistance but also aims to reduce liver fibrosis and steatosis, offering low-risk treatment options for individuals managing diabetes and its associated comorbidities.
AbolerIS Pharma
Series A in 2023
AbolerIS Pharma is a biotechnology company based in Nantes, France, focused on developing immune-modulators for the treatment of transplant rejection, graft-versus-host disease, and autoimmune diseases. Established in 2019, the company employs a unique therapeutic approach that aims to induce immune tolerance while preserving beneficial immune responses in various inflammatory and degenerative conditions. Its product portfolio includes Anti-CD45RC, a monoclonal antibody designed to deplete effector T cells, and IL-34, a cytokine that promotes the induction of tolerogenic macrophages and regulatory T cells. AbolerIS Pharma's innovative strategies enable researchers to advance novel drug development in areas with significant unmet medical needs.
Cikisi
Seed Round in 2023
Cikisi is a company that specializes in Web Intelligence, focusing on the collection, searching, and filtering of relevant online information for businesses and organizations. It develops and commercializes Cikisi WMT, a Web Intelligence Solution designed to provide real-time, tailored market insights. By leveraging artificial intelligence, the software streamlines the processes of collecting, processing, and disseminating pertinent data. This enables clients to make informed decisions more quickly, enhancing their ability to capitalize on valuable web information for their development and growth.
Santero Therapeutics
Series A in 2023
Santero Therapeutics is focused on developing innovative antibiotics aimed at addressing the challenges posed by multi-drug-resistant pathogens. The company creates medications that employ novel mechanisms of action to effectively combat infections resistant to traditional treatments. By providing therapies that maintain prolonged efficacy, Santero aims to improve patient outcomes and offer better-tolerated options for those afflicted with difficult-to-treat infections. Through its research and development efforts, Santero Therapeutics seeks to contribute to the fight against antibiotic resistance, a growing concern in modern medicine.
Sunrise
Series A in 2023
Sunrise is a medical technology company focused on improving the diagnosis and management of sleep disorders, particularly sleep apnea, which affects nearly one billion people worldwide. The company has developed a 3-gram sensor that allows for rapid and accurate at-home diagnosis of sleep conditions, utilizing trigeminal drive analysis to detect respiratory events. This innovative device is clinically validated for use in both adults and children and provides a cost-effective alternative to traditional in-lab sleep studies. Users receive a single-use sensor delivered to their home, which connects easily to their phone for seamless operation. Following the test, Sunrise facilitates consultations with certified sleep doctors or connections to local sleep centers, addressing a critical need in a healthcare landscape where 80% of sleep apnea cases remain undiagnosed.
Exthand
Pre Seed Round in 2022
Exthand specializes in open banking solutions that enable clients to connect to the APIs of 95% of banks across Europe, the UK, and Israel through a single interface. This connectivity facilitates instant account-to-account payments and the retrieval of financial data, making transactions faster and more cost-effective. The company's services support a range of applications, including personal finance management, credit scoring, cash flow management, and enhancements to e-commerce and marketplace platforms. By streamlining access to banking information, Exthand aims to improve financial processes for businesses and consumers alike.
Aerospacelab
Series B in 2022
Aerospacelab SA, founded in 2017 and headquartered in Mont-Saint-Guibert, Belgium, specializes in the development and manufacture of small satellites equipped with advanced sensors. The company focuses on creating satellite imagery technology that captures high-resolution optical data, allowing for frequent data collection. In addition to satellite production, Aerospacelab develops tools that utilize artificial intelligence and machine learning to automate various tasks, facilitating processes such as surveying and monitoring. This innovative approach enables customers to efficiently analyze substantial volumes of data and optimize the extraction of valuable insights from the information gathered.
Cake App
Seed Round in 2022
Cake App mission is to become the leading software technology provider that analyzes financial data to help people better understand, control and improve their finances, supported by a business model that shares our revenue with users.
HeartKinetics
Convertible Note in 2021
HeartKinetics focuses on developing artificial intelligence solutions for the rapid and precise detection of heart failure and cardio-toxicity. Utilizing a network of nine AI models trained on extensive patient data from the Mayo Clinic Platform, the company tests cardiac mechanical and electrical functions to identify issues such as ventricular ejection dysfunction and arrhythmias within minutes. Their innovative approach includes a lightweight solution that incorporates motion sensors in Holter ECG patches, aiming to predict cardiac complications and facilitate timely therapeutic decisions. Additionally, HeartKinetics offers a cloud-based healthcare application that transforms data into actionable insights, empowering healthcare professionals to tailor treatments to individual patient needs.
PDC*line Pharma
Series B in 2021
PDC*line Pharma is a clinical-stage biotech company based in France and Belgium, focused on developing innovative active immunotherapies for cancer. The company specializes in a proprietary allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line), which are loaded with cancer-specific antigens to stimulate a robust immune response. Founded in April 2014 in Grenoble by Laurent Levy and Joel Plumas, the company emerged from a research program at the French Blood Bank that developed the PDC line from a patient with PDC leukemia. PDC*line Pharma aims to enhance cancer treatment efficacy by producing potent and scalable PDC lines that can boost antitumor responses, including the activation of neoantigens and specific cytotoxic T-cells, offering a more effective alternative to conventional vaccines.
HireRing
Seed Round in 2021
HireRing is an on-demand staffing platform that connects employers with specialized recruitment agencies tailored to meet specific hiring needs. The platform streamlines the process, allowing employers to quickly submit vacancy requests and set their desired hiring fees upfront. This efficient marketplace enables recruitment agencies to select suitable business opportunities, ensuring that both employers and recruiters can engage effectively. As a result, HireRing facilitates a seamless hiring experience, enhancing the quality of recruitment services delivered to employers.
EsoBiotec
Seed Round in 2021
EsoBiotec is a Belgian biotechnology company dedicated to the discovery and development of novel cancer therapies. The firm focuses on empowering the human body to combat cancer through in vivo cell engineering. By creating innovative immunotherapies, EsoBiotec aims to provide cost-effective drugs and therapeutics that enhance accessibility, ensuring that patients can receive essential cancer treatments at lower costs.
Sortlist
Series B in 2021
Sortlist is a company that develops an online multi-criteria searching tool designed to assist businesses in finding suitable marketing and communication agencies. By leveraging professional networks and peer-to-peer recommendations, Sortlist enables marketing managers to efficiently discover potential partners in a rapidly evolving digital landscape. The platform caters to businesses of all sizes and sectors, streamlining the process of identifying service providers that align with specific needs and criteria. This solution allows clients to focus on enhancing their communication and marketing efforts rather than spending excessive time searching for the right agency.
Amyl Therapeutics
Series A in 2021
Amyl Therapeutics is a preclinical stage biotechnology company focused on developing therapeutics for various forms of amyloidosis. The company utilizes a novel mechanism to bind to the amyloid folds of toxic protein aggregates, including antibody light chain (AL) and transthyretin (TTR) aggregates, which contribute to systemic amyloidosis. Additionally, Amyl Therapeutics targets amyloid-β (Aβ), Tau, and α-synuclein aggregates associated with neurodegenerative diseases such as Alzheimer's and Parkinson's. By addressing multiple misfolded proteins responsible for both peripheral and central nervous system pathologies, the company aims to provide effective therapies that can prevent the accumulation of harmful protein aggregates in organs and the brain, offering new treatment options for patients suffering from these debilitating conditions.
Shyfter
Seed Round in 2021
Shyfter is a scheduling platform designed to enhance workforce management across various industries. It enables the creation and adjustment of employee schedules, leveraging AI to optimize staffing and productivity. The platform includes real-time time tracking, absence management, and communication channels for effective team coordination. Managers can quickly respond to staffing changes, approve leave requests, and ensure compliance with labor regulations, significantly reducing administrative tasks and minimizing scheduling conflicts. Shyfter also provides advanced analytics that deliver insights into workforce trends, aiding businesses in making informed decisions to improve operational efficiency and employee satisfaction. Tailored for small to medium-sized enterprises, Shyfter is customizable to fit specific organizational needs, making it a valuable tool for efficient workforce management.
ExeVir Bio
Series A in 2020
ExeVir Bio BV, founded in 2020 and based in Zwijnaarde, Belgium, specializes in developing single-domain antibody-based therapies aimed at combating viral infections. The company leverages a llama-derived antibody technology platform to create robust antiviral treatments that offer broad protection against coronaviruses. Notably, it is developing VHH72-FC, an antibody that targets a highly conserved region on the spikes of SARS-CoV-2, crucial for the virus's entry into human cells. ExeVir Bio's rapid response platform for antivirals allows for an agile approach to emerging health threats, enabling the swift generation of drug candidates. The therapeutics produced through this innovative technology are designed to be stable, cost-effective, and accessible on a global scale.
OncoDNA
Series B in 2020
OncoDNA, established by experts with over six decades of combined experience in medical diagnostics, specializes in precision medicine for cancer and genetic diseases. The company offers clinical guidance and real-time monitoring for late-stage cancer patients, aiding clinicians, researchers, and biopharma companies in advancing cancer and genetic disease treatments.
PDC*line Pharma
Series B in 2020
PDC*line Pharma is a clinical-stage biotech company based in France and Belgium, focused on developing innovative active immunotherapies for cancer. The company specializes in a proprietary allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line), which are loaded with cancer-specific antigens to stimulate a robust immune response. Founded in April 2014 in Grenoble by Laurent Levy and Joel Plumas, the company emerged from a research program at the French Blood Bank that developed the PDC line from a patient with PDC leukemia. PDC*line Pharma aims to enhance cancer treatment efficacy by producing potent and scalable PDC lines that can boost antitumor responses, including the activation of neoantigens and specific cytotoxic T-cells, offering a more effective alternative to conventional vaccines.
Utopix Pictures
Seed Round in 2019
Utopix Pictures SA is a Belgium-based company founded in 2015 that operates a platform designed to connect users with professionals in the photography, film, and imaging sectors. The company aims to simplify the process of finding the right photographer or videographer to meet specific project needs. By leveraging a network of skilled professionals, Utopix Pictures assists clients in transforming their ideas into compelling visual content efficiently and effectively.
Cognivia
Series B in 2019
Cognivia specializes in creating analytical tools that enhance and expedite the clinical development of new medicines. The company focuses on developing predictive techniques that improve the clinical evaluation of drugs and other therapeutics. By addressing key sources of variability in clinical trial data, Cognivia enables clients to better identify and manage challenges, ultimately leading to more efficient and effective clinical trials.
Smartbeam
Seed Round in 2019
Smartbeam is a construction technology platform that facilitates connections among stakeholders in real estate construction projects while enhancing financial monitoring at construction sites. The platform offers features such as automated data collection and analysis, as well as real-time budget tracking, which aids in efficient budget management. By supporting collaboration from the pre-construction phase through to the construction phase, Smartbeam enables construction professionals to streamline workflows, reduce rework, and increase productivity. The platform is designed to enhance budget reliability and minimize financial risks, ultimately improving project efficiency and collaboration.
Djengo
Seed Round in 2019
Djengo specializes in smart parking management and green mobility software designed for companies. Their flagship product, Commuty, optimizes the use of corporate parking and office space through an automated reservation system. The platform manages various parking needs, including those for visitors, individuals with reduced mobility, carpoolers, and bicycles, as well as electric vehicle chargers. Additionally, Djengo offers a ridesharing facility that facilitates home-to-work commuting by providing an online and mobile platform for peer-to-peer ridesharing and carpooling, enhancing the efficiency of transportation solutions for businesses and their employees.
Commuty
Seed Round in 2019
Commuty is a Belgium-based company that specializes in developing web and mobile applications for parking and mobility management. Founded in 2014, Commuty offers a smart parking management platform that organizes parking spot allocations and bookings in accordance with company policies, thereby enhancing flexibility and efficiency. The application also promotes alternative transportation methods, including carpooling and cycling, by connecting users with similar routes, managing shared bicycle usage, and automating kilometer refunds. Through these services, Commuty aims to facilitate mobility changes for employers and employees alike, ultimately leading to cost savings and reduced logistical constraints.
Sortlist
Series A in 2019
Sortlist is a company that develops an online multi-criteria searching tool designed to assist businesses in finding suitable marketing and communication agencies. By leveraging professional networks and peer-to-peer recommendations, Sortlist enables marketing managers to efficiently discover potential partners in a rapidly evolving digital landscape. The platform caters to businesses of all sizes and sectors, streamlining the process of identifying service providers that align with specific needs and criteria. This solution allows clients to focus on enhancing their communication and marketing efforts rather than spending excessive time searching for the right agency.
Minoryx Therapeutics
Series B in 2018
Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.
Chromacure
Venture Round in 2018
ChromaCure is engaged in the development of innovative cancer therapies, focusing on discovering first-in-class small molecule therapeutics to address unmet needs in oncology. The company is initiating a drug development program aimed at identifying new candidates that selectively and potently inhibit cancer targets. This initiative seeks to provide novel treatment options for multiple forms of cancer, either as standalone therapies or in combination with existing immunotherapy or chemotherapy approaches. Through its efforts, ChromaCure aims to enhance the therapeutic landscape for cancer patients, offering potential new solutions for various cancer types.
Ncardia
Series B in 2017
Ncardia is a biotechnology company focused on expediting the drug discovery and development process. The company leverages human induced pluripotent stem cell (hiPSC) technology to create predictive human cellular assay systems, which are used for safety and efficacy testing of drug candidates. Additionally, Ncardia enhances cardiovascular and neural drug screening, providing researchers and drug discovery companies with tools to better understand human disease biology. This approach aims to accelerate the overall drug discovery process, facilitating the development of safer and more effective therapeutic options.
Ncardia
Venture Round in 2017
Ncardia is a biotechnology company focused on expediting the drug discovery and development process. The company leverages human induced pluripotent stem cell (hiPSC) technology to create predictive human cellular assay systems, which are used for safety and efficacy testing of drug candidates. Additionally, Ncardia enhances cardiovascular and neural drug screening, providing researchers and drug discovery companies with tools to better understand human disease biology. This approach aims to accelerate the overall drug discovery process, facilitating the development of safer and more effective therapeutic options.
Opinum
Series A in 2016
Opinum, headquartered in Braine l'Alleud, Belgium, specializes in developing digital web-based software that focuses on energy and environmental data management. The company's flagship product, the Opinum Data Hub, supports energy and environmental stakeholders in their digital transformation by facilitating all stages of the data management value chain. This platform allows users, primarily large private and public service companies, energy suppliers, and energy management experts, to analyze and visualize data related to asset consumption, including gas, water, and electricity. By enabling businesses to track and regulate their energy usage, Opinum empowers them to focus on their core competencies while effectively managing their energy consumption.
X4C
Seed Round in 2016
X4C specializes in developing advanced molecular coatings for life science applications, focusing on in vitro diagnostics. The company utilizes innovative monolayer chemical coating technology to create robust organic monolayers that can be easily modified, allowing for enhanced functionality of various substrates. Their product offerings include nanoparticles and calixarenes, along with custom services tailored to meet specific industry needs. X4C's coatings are designed for a range of applications, including diagnostics, medical devices, electronics, and optics, ensuring that healthcare professionals can maintain the inherent properties of materials while enhancing their performance.
Opinum
Series A in 2016
Opinum, headquartered in Braine l'Alleud, Belgium, specializes in developing digital web-based software that focuses on energy and environmental data management. The company's flagship product, the Opinum Data Hub, supports energy and environmental stakeholders in their digital transformation by facilitating all stages of the data management value chain. This platform allows users, primarily large private and public service companies, energy suppliers, and energy management experts, to analyze and visualize data related to asset consumption, including gas, water, and electricity. By enabling businesses to track and regulate their energy usage, Opinum empowers them to focus on their core competencies while effectively managing their energy consumption.
Opinum
Seed Round in 2015
Opinum, headquartered in Braine l'Alleud, Belgium, specializes in developing digital web-based software that focuses on energy and environmental data management. The company's flagship product, the Opinum Data Hub, supports energy and environmental stakeholders in their digital transformation by facilitating all stages of the data management value chain. This platform allows users, primarily large private and public service companies, energy suppliers, and energy management experts, to analyze and visualize data related to asset consumption, including gas, water, and electricity. By enabling businesses to track and regulate their energy usage, Opinum empowers them to focus on their core competencies while effectively managing their energy consumption.
Calyos
Venture Round in 2012
Calyos is a company that specializes in thermal regulation systems, particularly focusing on advanced loop heat pipe cooling products. Originating from the space industry, Calyos leverages its extensive expertise and scalable manufacturing capabilities alongside patented technologies. The company's innovative systems utilize a dielectric fluid that effectively absorbs heat and boils at low temperatures, providing efficient cooling solutions for high-performance electronics. These products are applicable across various sectors, including servers, renewable energy systems, and telecommunication equipment. By eliminating thermal limitations, Calyos empowers clients to design competitive and reliable electronic products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.